Connect with us

Movements

Aphria to offer Medical Cannabis in Paraguay

mm

Published

on

Aphria to offer Medical Cannabis in Paraguay

Aphria has become the cannabis business’s black sheep of late, with accusations from short-sellers viewing the inventory dip drastically over the last few months as both sides want to convince the markets.

With one big criticism of this firm being it is South and Latin American operations, the company has doubled down within this field since it announced today they will be supplying medical cannabis to some significant pharmaceutical distributor in the nation.

The business revealed it had signed a Letter of Intent with Insumos Medicos S.A., a significant pharmaceutical manufacturing, export, and distribution business in Paraguay. Insumos retains the distinction of becoming among the best vendors of pharmaceuticals to hospitals in the nation, and may radically increase the vulnerability of Aphria goods around the nation.

As part of the arrangement, Insumos will even enroll Aphria’s medical cannabis with Paraguay’s Ministry of Public Health and Social Wealthfare alongside different licenses required. When the arrangement comes into effect, Paraguay is the third nation in Latin America which Aphria ships cannabis also, together with both being Colombia and Argentina.

“Latin America continues to represent a significant growth opportunity over the worldwide medical cannabis business, and we’re eager to be one of the very first to enter the fast-emerging marketplace in Paraguay. Our strategic partner, Isnumos, is well-positioned to establish a major presence for the organization’s products around the nation,” stated President Jakob Ripshtein. “Aphria will continue to enlarge its footprint at the most strategic markets in Latin America and across the globe through its diversified strategy to innovation, partnership and growth.”

Also Read: Washington state regulators made new rules for marijuana edibles

Among the biggest criticisms leveled at Aphria by short-sellers was that lots of the organization’s Latin American imports were allegedly bought at”significantly inflated rates,” many occasions what those resources were worth. Aphria officials have to respond to such accusations, choosing instead to proceed with their present Latin American growth approach.

The organization last week said that they had been doing a”detailed review” of the acquisitions in the region. But many investors have had sufficient, together with one law firm declaring they intend to engage in a lawsuit against Aphria for supposed offenses under the Securities Exchange Act within the previous six months.

Aphria stocks have recovered somewhat in the extreme decline they saw before a week, using today’s trading session viewing stocks fall a mere 5%, compared to the extreme 50 percentage movements which were common only a couple of days back.

About Aphria 

Aphria is a top worldwide cannabis firm driven by an unrelenting dedication to our clients, product quality and innovation. Headquartered at Leamington, Ontario — the greenhouse funding of Canada — Aphria has been setting the benchmark for its low-cost creation of safe, pure and clean pharmaceutical-grade cannabis at scale, increased in the many ordinary conditions possible.

Focusing on untapped opportunities and endorsed by the latest technology, Aphria is dedicated to bringing a breakthrough invention to the worldwide cannabis marketplace. The organization’s portfolio of brands is grounded in expertly-researched customer insights developed to satisfy the needs of each consumer section.

Also Read: Cresco Labs to open its first Cannabis Medical Dispensary in Ohio

Rooted in our creators’ multi-generational experience in commercial agriculture, Aphria pushes sustainable long-term shareholder value via a diversified strategy to innovation, strategic partnerships, and international growth, with a presence in over 10 countries across 5 continents.

Source

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Movements

3 Developments in CBD for the Food and Beverage Industry in 2020

mm

Published

on

Developments in CBD for the Food and Beverage

In 2019, the cannabidiol industry saw considerable growth, with the upward trend set to continue in 2020.

Despite the absence of federal guidelines, many CBD retailers delving into the food and beverage industry need to know about the three development points that may affect the sale of CBD products and the sector as a whole.

Clarification from the FDA

The Food and Drug Administration or FDA handed out several warning letters to CBD sellers, and as well as acknowledged the data gap and unanswered questions regarding CBD toxicity back in November 2019. Based on the Consumer Update published by the FDA, CBD incorporated into food or marketing as a dietary supplement is still illegal.

The FDA has included in its announcement the agency’s plan to explore other pathways that other CBD products can potentially be marketed with legal consent. It also looks forward to providing updates on the agency’s progress with the approach to be used on such products in the next few weeks.

Following this November announcement and the warning letters, CBD food, and beverage sellers need to be aware of the FDA’s next advisory regarding the products and how they could be lawfully marketed in 2020.

State and local response

The lack of federal guidance has prompted states to take matters in their own hands and craft a regulatory patchwork. However, these rules come in conflict with other established regulations across the US. In Maryland and New York, CBD-infused drinks and food are illegal. In the latter, city officials have sanctioned five restaurants that sell CBD edibles. The penalties range from $200-$650.

Industry players should watch out for the actions respective states will take amid the scarce federal regulation. New York has already passed a new law to take effect in March 2020, establishing the regulatory framework for CBD sale. New rules are bound to be issued by officials in the coming weeks.

Litigation

Class action litigation in the CBD industry is expected to rise in number this year, especially in cases concerning the food and beverage companies that sell CBD-infused products. Several lawsuits on the federal level have been filed against CBD manufacturers that allegedly violate the consumer protection laws of a state.

Industry experts predict that an avalanche of CBD-related complaints and lawsuits is imminent in 2020.

Further action

State and federal officials are set on determining the right course of action to take regarding CBD. Several private plaintiffs are also waiting for the developments in the food and beverage sector of the CBD industry. The high availability of CBD and CBD-containing products and the FDA’s latest pronouncement can stir a commotion in the private sector.

Cannabidiol manufacturers should, therefore, be on the lookout for any new changes or regulations in the industry to avoid legal complications and ensure that the CBD items they produce are lawfully allowed for sale.

Continue Reading

Movements

CBD Industry Goes Local, citing ‘Wild Wild West’

mm

Published

on

CBD Industry Goes Local, citing ‘Wild Wild West’

CBD is being hyped up across states, but the budding industry in Michigan is still navigating through the unclear regulatory landscape. CBD or cannabidiol was initially dismissed as a marijuana relative, but its alleged health and wellness benefits make it an early crowd favorite.

Today, CBD is everywhere in Michigan and is touted as a wellness product that doesn’t give the users a high, unlike its cousin marijuana. It’s found in shelves of Kroger and Family Video, and are sold as oils, bath products, and lotions. Some people feed it to their pet horses or infused them in ice cream.

Banking on CBD

Mother Earth Natural Health sibling owners Arianna and Tory Welsh started in 2016 when their father wanted a pain reliever that does not have psychoactive effects like medical marijuana. Today, they have three store branches and two more in the works for next year. They expect a 300-400% growth in sales for 2019.

The local market is now filled with the first harvest of industrial hemp since World War II. Michigan’s pilot program prompted Gov. Gretchen Whitmer to view the hemp industry as a potential enterprise creator. In early November, Michigan issued 572 licenses for growers and 433 permits for processor-handlers.

Welsh believes that Michigan-made CBD oil will be made available in as early as December or in January.

Urban Roots CBD LLC, a Monroe-based manufacturer, produces CBD tinctures, gummies, pet oil, topical creams, and more using out-of-state sourced hemp. However, the company’s co-founders Alex Kolpacke and Brandon Koz are hoping to become entirely Michigan-sourced.

All about hemp

Hemp is a variety of Cannabis sativa L. that does not contain more than 0.3% tetrahydrocannabinol (THC) content, the active component responsible for the high in marijuana. CBD is the non-psychotropic compound that can be extracted from the hemp and marijuana variety, but the federal law based on the 2018 Farm Bill specifies hemp-derived CBD as legal.

Last March, the Michigan DA and Bureau of Marijuana Regulation released CBD guidelines, although rules are still shifting due to the new interim rules issued by the USDA regarding industrial hemp. However, not one agency claims to govern sales for CBD in Michigan, adding to the confusion and murky regulation on the substance.

CBD has gotten famous over the years due to its alleged health and wellness benefits, alleviating conditions like pain, anxiety, stress, and even sleep deprivation. There has been strong clinical evidence for CBD’s effectiveness in helping with epilepsy in children, but experts believe that more research should be done to prove the other therapeutic claims of CBD.

Trey Malone, assistant professor, an economist at Michigan State University expresses his uncertainty on where the CBD market is headed. There is a lot of confusion, especially considering that the substance was included as a Schedule 1 in the Controlled Substances Act not long ago.

The CBD industry is dubbed by many as the “Wild Wild West” due to the inconsistency of quality, regulations, and health benefits. Malone cites the lack of data for consumer trends on CBD.

Growth and uncertainty

CBD’s lack of clarity in regulations was evident when the Detroit Health Department cracked down the sale of CBD-infused drinks, which are currently still not FDA-approved for purchase and consumption.

However, known retailers like Family Video now sell gummies, edibles, and CBD water in Michigan. Several others are doing the same amid the FDA’s lack of approval on CBD food intake.

CBD as food additives is still not federally legal, according to Detroit-based lawyer and owner of a law firm, Atty. Scott Roberts. He also notes that the rule is not actively enforced due to the current period of uncertainty in the CBD market today.

Based on a report by The Nielsen Co., the cannabis market can grow to a $6B industry in 2025. Brightfield Group also predicts the market to grow to $5B by the end of this year, with a foreseeable growth of up to $23.7B by 2023.

Continue Reading

Movements

Senator Relays Personal Experience with Cannabidiol

mm

Published

on

Senator Relays Personal Experience with CBD

A confirmation hearing for the Food and Drug Administration commissioner by the Senate veered towards the discussion of cannabidiol or CBD, as senators asked about the federal regulation circling the substance.

Lawmaker Pat Roberts recounted during the discussion his personal experience with the use of CBD oil, for which he expressed particular interest in the agency’s take on the said product.

Roberts Points Out Issues on CBD

Pat Roberts, a Kansas Republican lawmaker, recalls his wife encouraging him to try applying topical CBD oil on his bad “football” knees. However, the substance failed to bring pain relief, which also prompted him to discuss the lack of regulation regarding the product.

The Trump nominee for FDA commissioner being questioned at the confirmation hearing was Dr. Stephen Hahn. Roberts pointed out to him that there have been several reports and studies that show labeling inaccuracy on CBD products. He also voiced concern on the unregulated market, saying that there are many questions about the safety of these hemp-derived products.

Roberts also mentioned how CBD is now being used for everything, jokingly adding hair growth as an example. He went on to say that farmers are also pushing for a robust framework for such products since it is an expanding market, and growers want in on it.

Hahn answered by agreeing that CBD is now widely accessible and needs more data, research, and science to prove its efficacy and safety for consumers. He also stated that the FDA is in the process of creating a transparent and precise framework for CBD from a medical perspective.

Roberts is currently the Agriculture Committee chairman of the Senate.

CBD’s lack of federal regulation

Several industry critics call out the FDA for dragging the rulemaking process so that issues can be addressed with official rules. As of writing, the agency is yet to release federal guidelines on CBD use, which also frustrates industry players like growers, manufacturers, and sellers.

Hemp-derived products like CBD have been federally legalized since December 2018, when the Farm Bill was successfully passed into law. However, the market is still mostly unregulated since the FDA has not issued an approval for many CBD products that are circulating the industry today.

There is only one CBD-infused medication that the FDA recognizes, which is the Epidiolex. This drug is used to treat intractable epilepsy.

The agency is struggling to hand out regulations, and it may partly be due to the lack of quantifiable scientific research discussing this hemp derivative. There is a significant lack of evidence when it comes to proving therapeutic claims involving CBD.

Although lacking proof, cannabidiol is widely popular for its non-psychoactive properties since it does not have tetrahydrocannabinol or THC, the cannabis component responsible for the high that users experience in marijuana.

CBD is believed to be a natural cure-all for many health conditions, including anxiety, insomnia, cancer, Parkinson’s disease, several types of pain, and more.

Continue Reading

Trending